Kenneth Myszkowski's Insider Trades & SAST Disclosures
Kenneth Myszkowski's most recent trade in Arrowhead Pharmaceuticals Inc. was a trade of 100,000 Common Stock done . Disclosure was reported to the exchange on Jan. 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kenneth Myszkowski.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2025 | 100,000 | 500,600 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.68 per share. | 04 Jan 2025 | 17,765 | 482,835 (0%) | 0% | 19.7 | 349,615 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 04 Jan 2025 | 10,000 | 455,433 (0%) | 0% | 19.7 | 196,900 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 04 Jan 2025 | 9,402 | 473,433 (0%) | 0% | 20.1 | 188,980 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.70 per share. | 04 Jan 2025 | 8,000 | 465,433 (0%) | 0% | 19.7 | 157,600 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.19 per share. | 06 Mar 2024 | 40,000 | 400,600 (0%) | 0% | 35.2 | 1,407,600 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 75,000 | 456,704 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Myszkowski Kenneth | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.65 per share. | 04 Jan 2024 | 8,904 | 440,600 (0%) | 0% | 35.7 | 317,428 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.97 per share. | 04 Jan 2024 | 5,800 | 449,504 (0%) | 0% | 35.0 | 202,826 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.04 per share. | 04 Jan 2024 | 1,400 | 455,304 (0%) | 0% | 34.0 | 47,656 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.20 per share. | 27 Jun 2023 | 15,000 | 381,704 (0%) | 0% | 36.2 | 543,000 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 60,000 | 396,704 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Sep 2022 | 96,676 | 367,329 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.00 per share. | 05 Jan 2022 | 16,528 | 471,569 (0%) | 0% | 62 | 1,024,736 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.50 per share. | 05 Jan 2022 | 15,908 | 488,097 (0%) | 0% | 60.5 | 962,434 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 63.95 per share. | 05 Jan 2022 | 3,786 | 464,005 (0%) | 0% | 64.0 | 242,115 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 63.17 per share. | 05 Jan 2022 | 3,778 | 467,791 (0%) | 0% | 63.2 | 238,656 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 60,000 | 504,005 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 81.02 per share. | 11 Jan 2021 | 11,597 | 445,446 (0%) | 0% | 81.0 | 939,589 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 81.00 per share. | 11 Jan 2021 | 1,441 | 444,005 (0%) | 0% | 81 | 116,721 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 72.63 per share. | 06 Jan 2021 | 25,166 | 457,043 (0%) | 0% | 72.6 | 1,827,807 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 71.77 per share. | 06 Jan 2021 | 4,359 | 482,209 (0%) | 0% | 71.8 | 312,845 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.75 per share. | 06 Jan 2021 | 1,100 | 486,568 (0%) | 0% | 70.8 | 77,825 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2021 | 60,000 | 487,668 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 43,505 | 0 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.54 per share. | 09 Nov 2020 | 43,505 | 471,173 (0%) | 0% | 14.5 | 632,563 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 69.04 per share. | 09 Nov 2020 | 25,840 | 445,333 (0%) | 0% | 69.0 | 1,783,994 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 69.86 per share. | 09 Nov 2020 | 17,665 | 427,668 (0%) | 0% | 69.9 | 1,234,077 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 54.04 per share. | 20 Oct 2020 | 29,166 | 427,668 (0%) | 0% | 54.0 | 1,576,131 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.15 per share. | 20 Oct 2020 | 29,166 | 456,834 (0%) | 0% | 6.2 | 179,371 | Common Stock |
| Arrowhead Pharmaceuticals ... | Kenneth Myszkowski | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2020 | 29,166 | 43,505 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges